Showing 1991-2000 of 4063 results for "".
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- iVeena Submits IND Application to the FDA for Phase 2 Clinical Trial for Pediatric Myopiahttps://modernod.com/news/iveena-submits-ind-application-to-the-fda-for-phase-2-clinical-trial-for-pediatric-myopia/2482830/iVeena Delivery Systems announced the submission of an investigational new drug (IND) application to the FDA for IVMED-85 for the treatment of pediatric myopia. IVMED-85 is a new chemical entity (NCE), p
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- Galimedix Establishes SAB in Advance of Phase 2 Study of GAL-101 for Dry AMDhttps://modernod.com/news/galimedix-therapeutics-establishes-scientific-advisory-board-in-advance-of-phase-2-study-of-gal-101-for-dry-amd/2482313/Galimedix Therapeutics has formed a Scientific Advisory Board (SAB) to provide advice and direction to the company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD). The SAB consists of retina experts from both clinical prac
- EyePoint Begins Phase 2 VERONA Clinical Trial of EYP-1901 to Treat Diabetic Macular Edemahttps://modernod.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/EyePoint Pharmaceuticals, a company focused on therapeutics for retinal diseases, announced that the first patient has been dosed in the VERONA clinical trial of the company’s EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vor
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Oxurion Announces New Data on THR-149 Phase 2 KALAHARI Clinical Trial in DME at the Angiogenesis 2022 Conferencehttps://modernod.com/news/oxurion-announces-new-data-on-thr-149-phase-2-kalahari-clinical-trial-in-dme-at-the-angiogenesis-2022-conference/2480637/